Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 3: Procedure- and disease-related adverse events*
Randomized Treatment
Hydrogel Bare Platinum
No. % No. %
Procedural aneurysm rupture 9 3.6 8 3.2
Coil migration 15 6.0 10 4.0
Parent artery occlusion 4 1.6 8 3.2
Thromboembolic complication 14 5.6 25 10.0
Other procedure-related adverse events 8 3.2 9 3.6
Intra-arterial thrombolysis used 20 8.0 26 10.4
Neurologic deterioration immediately after coiling 18 7.2 17 6.8
Rebleed before discharge 0 0 2 0.8
Delayed ischemic neurologic deficit 34 13.7 38 15.2
Cerebral hematoma 9 3.6 11 4.4
Cardiorespiratory 11 4.4 13 5.2
Other disease-related^† 13 5.2 9 3.6
* Events, especially procedural ones, may not have resulted in clinical sequelae.
† See “Results” for explanatory notes.

	Randomized Treatment
	Hydrogel		Bare Platinum
	No.	%	No.	%
Procedural aneurysm rupture	9	3.6	8	3.2
Coil migration	15	6.0	10	4.0
Parent artery occlusion	4	1.6	8	3.2
Thromboembolic complication	14	5.6	25	10.0
Other procedure-related adverse events	8	3.2	9	3.6
Intra-arterial thrombolysis used	20	8.0	26	10.4
Neurologic deterioration immediately after coiling	18	7.2	17	6.8
Rebleed before discharge	0	0	2	0.8
Delayed ischemic neurologic deficit	34	13.7	38	15.2
Cerebral hematoma	9	3.6	11	4.4
Cardiorespiratory	11	4.4	13	5.2
Other disease-related^†	13	5.2	9	3.6